Publication Cover
Endothelium
Journal of Endothelial Cell Research
Volume 14, 2007 - Issue 4-5
12
Views
5
CrossRef citations to date
0
Altmetric
Regular Articles

Comparison of Effects of Epigallocatechin-3-gallate on Hypoxia Injury to Human Umbilical Vein, RF/6A, and ECV304 Cells Induced by Na2S2O4

, , , , &
Pages 227-231 | Received 18 Sep 2006, Accepted 09 Jun 2007, Published online: 13 Jul 2009
 

Abstract

Hypoxia is related to the etiology of numerous pathological disease states, such as the formation of tumors or diverse retinopathies. Epigallocatechin-3-gallate (EGCG), a potent polyphenolic antioxidant and antiangiogenic compound found in green tea, has been shown to suppress the growth of blood vessels necessary for the growth of tumors and the induction of retinopathies. However, only a few studies have been carried focusing on the protective effects of EGCG on hypoxia-induced injury of cultured endothelial cells. The present study investigated the effects of EGCG on Na2S2O4-induced hypoxic injury in three types of cultured endothelial cells, primary isolates of normal human umbilical vein endothelial cells (HUVECs), and two transformed endothelial cells lines, RF/6A and ECV304. Our results indicated that Na2S2O4 inhibited the growth of HUVE, RF/6A, and ECV304 cells in a dose-dependent manner; EGCG also exerted inhibitory effects on the growth of the three cell types, but the toxicity of EGCG to HUVECs was less than to RF/6A and ECV304 cells. The viability of HUVE, RF/6A, and ECV304 cells treated with EGGC were the lowest at 24, 24, and 36 h, respectively, and the IC50 of EGCG were 420 ± 8.0, 125 ± 7.1, and 75 ± 5.1 μM, respectively. Furthermore, EGCG, an efficient nontoxic agent, protected all three cell types from Na2S2O4-induced hypoxia injury, providing partial protection from hypoxia-induced injury in normal endothelial cells at 100, 30, and 10 μ M for HUVE, RF/6A, and ECV304 cells, respectively.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.